COVID-19 Presented with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal Haemoglobinuria

Abstract

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired clonal haematological disease characterized by complement-mediated haemolysis, bone marrow failure and venous thrombosis. Anticomplement therapy eculizumab improves survival and reduces complications. Severe acute respiratory distress syndrome corona virus 2 (SARS-CoV-2) disease 2019 (COVID-19) is associated with high incidence of both venous and arterial thrombosis in hospitalized patients with pneumonia. Deep venous thrombosis (DVT) as the presenting symptom of COVID-19 is a rare event. We describe a well-controlled PNH patient on eculizumab for more than 5 years who presented with DVT, while on warfarin, as the first sign of COVID-19. To our knowledge, this is the first described case of DVT in a PNH patient with COVID-19.

Keywords

COVID-19 - thrombosis - PNH - eculizumab - anticoagulation

Publication History

Received: 07 April 2021

Accepted: 19 July 2021

Article published online:
20 September 2021

• References

• 1 Risitano AM, Rotoli B. Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents. Biologics 2008; 2 (02) 205-222
• 2 Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol 2011; 153 (06) 709-720
• 3 Pu JJ, Brodsky RA. Paroxysmal nocturnal hemoglobinuria from bench to bedside. Clin Transl Sci 2011; 4 (03) 219-224
• 4 Lodigiani C, Iapichino G, Carenzo L. et al; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020; 191: 9-14
• 5 Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020; 46 (07) 763-771
• 6 Santoliquido A, Porfidia A, Nesci A. et al; Gemelli Against COVID-19 Group. Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. J Thromb Haemost 2020; 18 (09) 2358-2363
• 7 Hughes C, Nichols T, Pike M, Subbe C, Elghenzai S. Cerebral venous sinus thrombosis as a presentation of COVID-19. Eur J Case Rep Intern Med 2020; 7 (05) 001691
• 8 Hemasian H, Ansari B. First case of COVID-19 presented with cerebral venous thrombosis: a rare and dreaded case. Rev Neurol (Paris) 2020; 176 (06) 521-523
• 9 Davoodi L, Jafarpour H, Taghavi M, Razavi A. COVID-19 presented with deep vein thrombosis: an unusual presenting. J Investig Med High Impact Case Rep 2020; 8: 2324709620931239
• 10 Mohammadi S, Abouzaripour M, Hesam Shariati N, Hesam Shariati MB. Ovarian vein thrombosis after coronavirus disease (COVID-19) infection in a pregnant woman: case report. J Thromb Thrombolysis 2020; 50 (03) 604-607
• 11 Veyseh M, Pophali P, Jayarangaiah A, Kumar A. Left gonadal vein thrombosis in a patient with COVID-19-associated coagulopathy. BMJ Case Rep 2020; 13 (09) e236786
• 12 Rali P, O'Corragain O, Oresanya L. et al. Incidence of venous thromboembolism in coronavirus disease 2019: an experience from a single large academic center. J Vasc Surg Venous Lymphat Disord 2021; 9 (03) 585-591.e2
• 13 Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (06) 1421-1424
• 14 Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost 2020; 26: 1076029620938149
• 15 Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M. Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines. Swiss Med Wkly 2020; 150: w20301
• 16 Dobesh PP, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. Pharmacotherapy 2020; 40 (11) 1130-1151
• 17 Griffin M, Munir T. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. Ther Adv Hematol 2017; 8 (03) 119-126
• 18 Malato A, Saccullo G, Coco LL. et al. Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review. Blood Transfus 2012; 10 (04) 428-435
• 19 Kulasekararaj AG, Lazana I, Large J. et al. Terminal complement inhibition dampens the inflammation during COVID-19. Br J Haematol 2020; 190 (03) e141-e143
• 20 Valerio L, Riva N. Head, neck, and abdominopelvic septic thrombophlebitis: current evidence and challenges in diagnosis and treatment. Hamostaseologie 2020; 40 (03) 301-310
• 21 Shikdar S, Borogovac A, Mohamad E, Khawandanah M. COVID-19 infection in a patient undergoing treatment for paroxysmal nocturnal hemoglobinuria (PNH) with ravulizumab [preprint, version 1]. 2020 . Accessed November 16, 2020 at: https://doi.org/10.21203/rs.3.rs-84187/v1
• 22 Schüller H, Klein F, Lübbert M. et al. Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report. Ann Hematol 2020; 100 (03) 841-842
• 23 Diurno F, Numis FG, Porta G. et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 2020; 24 (07) 4040-4047
• 24 Vlaar APJ, de Bruin S, Busch M. et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol 2020; 2 (12) e764-e773
• 25 Clinicaltrials.Gov. CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients with COVID-19 Infection, Nested in the CORIMUNO-19 Cohort (CORIMUNO19-ECU). 2020 . Accessed November 22, 2020 at: https://clinicaltrials.gov/ct2/show/NCT04346797
• 26 Mastellos DC, Pires da Silva BGP, Fonseca BAL. et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol 2020; 220: 108598
• 27 Annane D, Heming N, Grimaldi-Bensouda L. et al; Garches COVID 19 Collaborative Group. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine 2020; 28: 100590